The treatment is the comprehensive care surrounding it." GLP-1 medications are transforming obesity and cardio-kidney-metabolic carebut they should be prescribed within a comprehensive clinical model that includes: Thorough medical evaluation Personalized treatment planning Ongoing medication management Nutrition, behavioral, and lifestyle support Longitudinal follow-up to optimize outcomes Read the JAMA study: #ObesityMedicine #GLP1 #CardiometabolicHealth #Telehealth #DigitalHealth #eCKM #CKM #FlyteHealth To view or add a comment, sign in Great perspective from Katherine Saunders, MD, FTOS As GLP-1 access continues to grow, its important to remember that the medication is only one piece of the puzzle
Consult endocrinologist
Jennifer Miller is a pediatric endocrinologist at the University of Florida, where she led trials that supported this drugs approval
I have been taking nrf2 and nrf1 protandim by lifevantage for 3wks and have seen no improvement and more spots
Antihypertensive Drugs Theoretically, niacin may increase the risk of hypotension when used with antihypertensive drugs
We also observed some added benefits of liraglutide treatment compared with colesevelam: Liraglutide showed beneficial effects on the dysmetabolic prediabetic-like state that also characterizes these patients